Does the media prefer OCS or CRBP?

In the previous week, Oculis had 6 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 9 mentions for Oculis and 3 mentions for Corbus Pharmaceuticals. Oculis' average media sentiment score of 0.92 beat Corbus Pharmaceuticals' score of 0.15 indicating that Oculis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corbus Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CRBP or SPRY?

In the previous week, ARS Pharmaceuticals had 1 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 4 mentions for ARS Pharmaceuticals and 3 mentions for Corbus Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 0.95 beat Corbus Pharmaceuticals' score of 0.15 indicating that ARS Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corbus Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ARS Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CRBP or CRMD?

In the previous week, Corbus Pharmaceuticals had 2 more articles in the media than CorMedix. MarketBeat recorded 3 mentions for Corbus Pharmaceuticals and 1 mentions for CorMedix. Corbus Pharmaceuticals' average media sentiment score of 0.15 beat CorMedix's score of 0.00 indicating that Corbus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corbus Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CorMedix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ALT or CRBP?

In the previous week, Altimmune had 1 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 4 mentions for Altimmune and 3 mentions for Corbus Pharmaceuticals. Corbus Pharmaceuticals' average media sentiment score of 0.15 beat Altimmune's score of -0.30 indicating that Corbus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Altimmune 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Corbus Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate CRBP or AVTE?

Corbus Pharmaceuticals currently has a consensus price target of $42.25, indicating a potential upside of 341.90%. Given Corbus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Corbus Pharmaceuticals is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Corbus Pharmaceuticals 2 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.60 Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings and valuation, CRBP or AVTE?

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Corbus Pharmaceuticals N/A N/A -$78.54M -$5.82 N/A Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A

Is CRBP or AVTE more profitable?

Corbus Pharmaceuticals' return on equity of -70.89% beat Aerovate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Corbus Pharmaceuticals N/A -70.89% -61.78% Aerovate Therapeutics N/A -90.19% -77.47%

Corbus Pharmaceuticals (CRBP) Competitors

$9.58 +0.18 (+1.91%)

As of 02:15 PM Eastern

Compare

CRBP vs. OCS, SPRY, CRMD, ALT, and AVTE

Should you buy Corbus Pharmaceuticals stock or one of its competitors? MarketBeat compares Corbus Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Corbus Pharmaceuticals include Oculis (OCS), ARS Pharmaceuticals (SPRY), CorMedix (CRMD), Altimmune (ALT), and Aerovate Therapeutics (AVTE).

How does Corbus Pharmaceuticals compare to Oculis?

Oculis (NASDAQ:OCS) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, media sentiment, institutional ownership and valuation.

Oculis currently has a consensus target price of $38.33, indicating a potential upside of 218.65%. Corbus Pharmaceuticals has a consensus target price of $42.25, indicating a potential upside of 341.90%. Given Corbus Pharmaceuticals' higher possible upside, analysts plainly believe Corbus Pharmaceuticals is more favorable than Oculis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.60

22.3% of Oculis shares are held by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are held by institutional investors. 3.5% of Corbus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Oculis has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market. Comparatively, Corbus Pharmaceuticals has a beta of 2.59, suggesting that its stock price is 159% more volatile than the broader market.

Corbus Pharmaceuticals has lower revenue, but higher earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oculis	$1.45M	481.03	-$119.44M	-$2.13	N/A
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$5.82	N/A

In the previous week, Oculis had 6 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 9 mentions for Oculis and 3 mentions for Corbus Pharmaceuticals. Oculis' average media sentiment score of 0.92 beat Corbus Pharmaceuticals' score of 0.15 indicating that Oculis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oculis	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corbus Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Corbus Pharmaceuticals has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. Oculis' return on equity of -56.78% beat Corbus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oculis	-8,460.67%	-56.78%	-45.62%
Corbus Pharmaceuticals	N/A	-70.89%	-61.78%

Summary

Oculis beats Corbus Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Corbus Pharmaceuticals compare to ARS Pharmaceuticals?

Corbus Pharmaceuticals (NASDAQ:CRBP) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

In the previous week, ARS Pharmaceuticals had 1 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 4 mentions for ARS Pharmaceuticals and 3 mentions for Corbus Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 0.95 beat Corbus Pharmaceuticals' score of 0.15 indicating that ARS Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corbus Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ARS Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Corbus Pharmaceuticals has a beta of 2.59, meaning that its share price is 159% more volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market.

Corbus Pharmaceuticals has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -200.00%. Corbus Pharmaceuticals' return on equity of -70.89% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corbus Pharmaceuticals	N/A	-70.89%	-61.78%
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%

Corbus Pharmaceuticals presently has a consensus price target of $42.25, indicating a potential upside of 341.90%. ARS Pharmaceuticals has a consensus price target of $28.20, indicating a potential upside of 429.48%. Given ARS Pharmaceuticals' higher possible upside, analysts plainly believe ARS Pharmaceuticals is more favorable than Corbus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.60
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Corbus Pharmaceuticals has higher earnings, but lower revenue than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$5.82	N/A
ARS Pharmaceuticals	$84.28M	6.28	-$171.30M	-$2.01	N/A

64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 3.5% of Corbus Pharmaceuticals shares are owned by company insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

ARS Pharmaceuticals beats Corbus Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Corbus Pharmaceuticals compare to CorMedix?

Corbus Pharmaceuticals (NASDAQ:CRBP) and CorMedix (NASDAQ:CRMD) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

CorMedix has higher revenue and earnings than Corbus Pharmaceuticals. Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$5.82	N/A
CorMedix	$311.71M	1.89	$163.05M	$2.13	3.52

Corbus Pharmaceuticals has a beta of 2.59, indicating that its stock price is 159% more volatile than the broader market. Comparatively, CorMedix has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market.

64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 3.5% of Corbus Pharmaceuticals shares are owned by insiders. Comparatively, 3.5% of CorMedix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Corbus Pharmaceuticals presently has a consensus price target of $42.25, indicating a potential upside of 341.90%. CorMedix has a consensus price target of $14.86, indicating a potential upside of 98.23%. Given Corbus Pharmaceuticals' higher probable upside, equities research analysts plainly believe Corbus Pharmaceuticals is more favorable than CorMedix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.60
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Corbus Pharmaceuticals had 2 more articles in the media than CorMedix. MarketBeat recorded 3 mentions for Corbus Pharmaceuticals and 1 mentions for CorMedix. Corbus Pharmaceuticals' average media sentiment score of 0.15 beat CorMedix's score of 0.00 indicating that Corbus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corbus Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CorMedix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CorMedix has a net margin of 45.25% compared to Corbus Pharmaceuticals' net margin of 0.00%. CorMedix's return on equity of 45.57% beat Corbus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corbus Pharmaceuticals	N/A	-70.89%	-61.78%
CorMedix	45.25%	45.57%	24.76%

Summary

CorMedix beats Corbus Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Corbus Pharmaceuticals compare to Altimmune?

Altimmune (NASDAQ:ALT) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

78.1% of Altimmune shares are owned by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. 1.6% of Altimmune shares are owned by insiders. Comparatively, 3.5% of Corbus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Altimmune has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market. Comparatively, Corbus Pharmaceuticals has a beta of 2.59, meaning that its stock price is 159% more volatile than the broader market.

In the previous week, Altimmune had 1 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 4 mentions for Altimmune and 3 mentions for Corbus Pharmaceuticals. Corbus Pharmaceuticals' average media sentiment score of 0.15 beat Altimmune's score of -0.30 indicating that Corbus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Altimmune	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Corbus Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Corbus Pharmaceuticals has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -42.57% beat Corbus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Altimmune	-214,860.98%	-42.57%	-35.57%
Corbus Pharmaceuticals	N/A	-70.89%	-61.78%

Altimmune presently has a consensus target price of $15.71, indicating a potential upside of 417.77%. Corbus Pharmaceuticals has a consensus target price of $42.25, indicating a potential upside of 341.90%. Given Altimmune's stronger consensus rating and higher possible upside, analysts plainly believe Altimmune is more favorable than Corbus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Altimmune	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.60

Corbus Pharmaceuticals has lower revenue, but higher earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Altimmune	$40K	14,755.41	-$88.09M	-$0.93	N/A
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$5.82	N/A

Summary

Altimmune beats Corbus Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Corbus Pharmaceuticals compare to Aerovate Therapeutics?

Corbus Pharmaceuticals (NASDAQ:CRBP) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

Corbus Pharmaceuticals has a beta of 2.59, indicating that its share price is 159% more volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market.

Corbus Pharmaceuticals currently has a consensus price target of $42.25, indicating a potential upside of 341.90%. Given Corbus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Corbus Pharmaceuticals is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.60
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. 3.5% of Corbus Pharmaceuticals shares are owned by company insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Corbus Pharmaceuticals had 3 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 3 mentions for Corbus Pharmaceuticals and 0 mentions for Aerovate Therapeutics. Corbus Pharmaceuticals' average media sentiment score of 0.15 beat Aerovate Therapeutics' score of 0.00 indicating that Corbus Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Corbus Pharmaceuticals	Neutral
Aerovate Therapeutics	Neutral

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$5.82	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

Corbus Pharmaceuticals' return on equity of -70.89% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corbus Pharmaceuticals	N/A	-70.89%	-61.78%
Aerovate Therapeutics	N/A	-90.19%	-77.47%

Summary

Corbus Pharmaceuticals beats Aerovate Therapeutics on 10 of the 13 factors compared between the two stocks.

Get Corbus Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRBP vs. The Competition

Export

Metric	Corbus Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$177.15M	$3.60B	$6.89B	$12.91B
Dividend Yield	N/A	3.77%	2.60%	10.01%
P/E Ratio	-1.64	7.44	280.55	25.57
Price / Sales	N/A	1,297.57	597.07	91.80
Price / Cash	N/A	103.44	72.11	49.40
Price / Book	1.14	17.29	13.00	6.10
Net Income	-$78.54M	-$12.52M	$3.49B	$348.05M
7 Day Performance	7.37%	4.21%	3.61%	4.87%
1 Month Performance	3.36%	-4.90%	-2.48%	-2.01%
1 Year Performance	7.43%	50.96%	74.07%	21.20%

Corbus Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRBP Corbus Pharmaceuticals	3.2528 of 5 stars	$9.56 +1.7%	$42.25 +341.9%	+0.6%	$177.15M	N/A	N/A	40	News Coverage Upcoming Earnings
OCS Oculis	3.4509 of 5 stars	$10.97 -0.5%	$38.33 +249.5%	-33.2%	$638.94M	$1.45M	N/A	2	News Coverage Upcoming Earnings Analyst Forecast
SPRY ARS Pharmaceuticals	2.6111 of 5 stars	$5.89 +2.2%	$28.20 +379.1%	-69.4%	$587.86M	$84.28M	N/A	90
CRMD CorMedix	1.7459 of 5 stars	$7.41 -2.6%	$14.86 +100.6%	-39.2%	$582.41M	$311.71M	3.49	30
ALT Altimmune	2.0417 of 5 stars	$2.91 -1.9%	$15.71 +440.9%	-14.2%	$578.56M	$36K	N/A	50	Positive News Upcoming Earnings Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRBP) was last updated on 8/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Corbus Pharmaceuticals (CRBP) Competitors

CRBP vs. OCS, SPRY, CRMD, ALT, and AVTE

How does Corbus Pharmaceuticals compare to Oculis?

Summary

How does Corbus Pharmaceuticals compare to ARS Pharmaceuticals?

Summary

How does Corbus Pharmaceuticals compare to CorMedix?

Summary

How does Corbus Pharmaceuticals compare to Altimmune?

Summary

How does Corbus Pharmaceuticals compare to Aerovate Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBP vs. The Competition

Corbus Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Corbus Pharmaceuticals (CRBP) Competitors

CRBP vs. OCS, SPRY, CRMD, ALT, and AVTE

How does Corbus Pharmaceuticals compare to Oculis?

Do analysts rate OCS or CRBP?

Do institutionals & insiders believe in OCS or CRBP?

Which has more risk & volatility, OCS or CRBP?

Which has stronger earnings and valuation, OCS or CRBP?

Does the media prefer OCS or CRBP?

Is OCS or CRBP more profitable?

Summary

How does Corbus Pharmaceuticals compare to ARS Pharmaceuticals?

Does the media refer more to CRBP or SPRY?

Which has more risk & volatility, CRBP or SPRY?

Is CRBP or SPRY more profitable?

Do analysts recommend CRBP or SPRY?

Which has better earnings & valuation, CRBP or SPRY?

Do insiders & institutionals believe in CRBP or SPRY?

Summary

How does Corbus Pharmaceuticals compare to CorMedix?

Which has better valuation and earnings, CRBP or CRMD?

Which has more volatility and risk, CRBP or CRMD?

Do insiders and institutionals hold more shares of CRBP or CRMD?

Do analysts rate CRBP or CRMD?

Does the media refer more to CRBP or CRMD?

Is CRBP or CRMD more profitable?

Summary

How does Corbus Pharmaceuticals compare to Altimmune?

Do institutionals & insiders believe in ALT or CRBP?

Which has more volatility and risk, ALT or CRBP?

Does the media prefer ALT or CRBP?

Is ALT or CRBP more profitable?

Do analysts prefer ALT or CRBP?

Which has preferable valuation and earnings, ALT or CRBP?

Summary

How does Corbus Pharmaceuticals compare to Aerovate Therapeutics?

Which has more risk and volatility, CRBP or AVTE?

Do analysts rate CRBP or AVTE?

Do institutionals and insiders believe in CRBP or AVTE?

Does the media refer more to CRBP or AVTE?

Which has preferable earnings and valuation, CRBP or AVTE?

Is CRBP or AVTE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBP vs. The Competition

Corbus Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools